blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3893901

EP3893901 - COMPOSITIONS AND METHODS FOR IMMUNOTHERAPIES [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  17.09.2021
Database last updated on 16.07.2024
FormerThe international publication has been made
Status updated on  20.06.2020
Most recent event   Tooltip27.12.2023New entry: Renewal fee paid 
Applicant(s)For all designated states
The Regents of the University of California
1111 Franklin Street
Twelfth Floor
Oakland, CA 94607 / US
[2021/42]
Inventor(s)01 / JEWETT, Anahid
10889 Wilshire Blvd, Suite 920
Los Angeles, CA 90095-7191 / US
 [2021/42]
Representative(s)Müller-Boré & Partner Patentanwälte PartG mbB
Friedenheimer Brücke 21
80639 München / DE
[2021/42]
Application number, filing date19895115.410.12.2019
[2021/42]
WO2019US65381
Priority number, dateUS201862778189P11.12.2018         Original published format: US 201862778189 P
[2021/42]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020123447
Date:18.06.2020
Language:EN
[2020/25]
Type: A1 Application with search report 
No.:EP3893901
Date:20.10.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 18.06.2020 takes the place of the publication of the European patent application.
[2021/42]
Search report(s)International search report - published on:IL18.06.2020
(Supplementary) European search report - dispatched on:EP02.12.2022
ClassificationIPC:A61K35/17, A61P35/00, C12N5/0783, C07K16/28, C12N5/0786, A61K35/15, A61K35/74, A61K35/745, A61K35/747, A61K39/00
[2023/01]
CPC:
C07K16/2833 (EP); A61K35/17 (US); A61K31/198 (US);
A61K31/337 (US); A61K33/243 (US); A61K35/74 (EP);
A61K35/741 (US); A61K35/744 (US); A61K35/745 (EP,US);
A61K35/747 (EP,US); A61K36/03 (US); A61K39/3955 (US);
A61K39/39558 (US); A61K39/4613 (EP); A61K39/464499 (EP);
A61P35/00 (EP,US); C07K16/2863 (EP); A61K2039/505 (EP);
A61K2239/26 (EP); A61K2239/31 (EP); A61K2239/38 (EP);
C07K2317/732 (EP) (-)
Former IPC [2021/42]A61K35/17, A61P35/00, C12N5/0783, C07K16/28, C12N5/0786, A61K35/15, A61K35/74
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/42]
TitleGerman:ZUSAMMENSETZUNGEN UND VERFAHREN FÜR IMMUNTHERAPIEN[2021/42]
English:COMPOSITIONS AND METHODS FOR IMMUNOTHERAPIES[2021/42]
French:COMPOSITIONS ET MÉTHODES POUR IMMUNOTHÉRAPIES[2021/42]
Entry into regional phase10.06.2021National basic fee paid 
10.06.2021Search fee paid 
10.06.2021Designation fee(s) paid 
10.06.2021Examination fee paid 
Examination procedure10.06.2021Examination requested  [2021/42]
20.06.2023Amendment by applicant (claims and/or description)
Fees paidRenewal fee
27.12.2021Renewal fee patent year 03
27.12.2022Renewal fee patent year 04
27.12.2023Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XY]WO2015039100  (UNIV PENNSYLVANIA [US]) [X] 1-5,7-14 * abstract, p. 2 line 24 - p. 3 line 34, example and claims * [Y] 6;
 [YA]WO2018112366  (UNIV CALIFORNIA [US]) [Y] 6 * abstract, p. 2 lines 8-25, example 1-7 and claims * [A] 1-5,7-15;
 [XY]WO2018160993  (OBSIDIAN THERAPEUTICS INC [US]) [X] 1-5,7-15 * abstract, paragraphs [0009]-[0054], in particular [0037] and [0053], [0326], [0349], examples 1-24 and claims * [Y] 6;
 [A]  - KAUR KAWALJIT ET AL, "Novel Strategy to Expand Super-Charged NK Cells with Significant Potential to Lyse and Differentiate Cancer Stem Cells: Differences in NK Expansion and Function between Healthy and Cancer Patients", FRONTIERS IN IMMUNOLOGY, (20170405), vol. 8, doi:10.3389/fimmu.2017.00297, pages 1 - 21, XP093000911 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.3389/fimmu.2017.00297
 [A]  - KOZLOWSKA ANNA K ET AL, "Adoptive transfer of osteoclast-expanded natural killer cells for immunotherapy targeting cancer stem-like cells in humanized mice", CANCER IMMUNOLOGY IMMUNOTHERAPY, SPRINGER, BERLIN/HEIDELBERG, vol. 65, no. 7, doi:10.1007/S00262-016-1822-9, ISSN 0340-7004, (20160331), pages 835 - 845, (20160331), XP035987454 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1007/s00262-016-1822-9
 [I]  - K KAUR, "Super-charged NK cells increase immune infiltration in the tumor microenvironment and inhibit tumor growth in humanized-BLT mice", UCLA ELECTRONIC THESES AND DISSERTATIONS, (20170101), XP055534916 [I] 1-15 * abstract/summary and pages 21 , 29-30, 97-107; page 57, Fig. 5; page 119, Fig. 1; page 121, Fig. 2; pages 116-121; page 2; table 1, page 100; page 113, Fig. 1 *
 [A]  - ELENI G ILIOPOULOU ET AL, "A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, (20100812), vol. 59, no. 12, ISSN 1432-0851, pages 1781 - 1789, XP019842246 [A] 1-15 * the whole document *
 [A]  - WANG X ET AL, "An six-amino acid motif in the @a3 domain of MICA is the cancer therapeutic target to inhibit shedding", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM NL, vol. 387, no. 3, doi:10.1016/J.BBRC.2009.07.062, ISSN 0006-291X, (20090925), pages 476 - 481, (20090716), XP026448303 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.bbrc.2009.07.062
International search[X]US2015238530  (JEWETT ANAHID [US]) [X] 1-5, 9-14, 18-32, 36-41, 45-59, 63-67, 70-74* Paras. 0015, 0055, Example 9 *;
 [X]  - BOLLARD, KAUR, K., "Super-charged NK cells increase immune infiltration in the tumor microenvironment and inhibit tumor growth in humanized-BLT mice", UCLA. ProQuest ID: Kaur_ucla_0031D_15321. MerrittID: ark:/13030/m5rv5hlc, (20170101), pages 21, 29 - 30, 97-107, URL: https://cloudfront.escholarship.org/dist/prd/content/qt0t3834hd/qt0t3834hd.pdf, XP055534916 [X] 1-19, 23-46, 50-71 * ; page 57, Fig. 5; page 119, Fig. 1; page 121, Fig. 2; pages 116-121; page 2; table 1, page 100; page 113, Fig. 1 *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.